This study aimed to provide a preliminary exploration of CD94 expression in canine leukemia and lymphoma, both within the tumor immune microenvironment and on tumor cells, by applying the novel canine CD94 mAb in a multicolor flow cytometric (FCM) panel with CD3 and CD8 to clinical samples from client-owned dogs. This evidence concerns the gene CD8A and neoplasm.